Cited by 9Diabetes Management and ResearchHyperglycemia and glycemic control in critically ill and hospitalized patientsDiabetes Treatment and Management

Attitudes and behaviors with diabetes technology use in the hospital: multicenter survey study in the United States

Open access
Madhun, Nabil Z., Galindo, Rodolfo J., Donato, Jessica, Hwang, Patricia R., Shabir, Hassan F., Fowler, Michael J., Molitch-Hou, Ethan, Bena, James F. +2 more·2023·Diabetes Technology & Therapeutics

Abstract

Objective: To assess the attitudes, behaviors, and barriers with diabetes technology use in the general medicine hospital wards. Research Design and Methods: The authors developed a nonincentivized web-based anonymous survey that captured demographic and practice data regarding continuous subcutaneous insulin infusion (CSII) and continuous glucose monitor (CGM) use in the hospital. Setting: Four large hospital systems in the United States. Results: Among 128 survey respondents, 76%, 10%, and 6% were hospitalists, advanced practice providers, and primary care physicians, respectively. The majority of respondents rated the treatment of inpatient hyperglycemia (96%) and the continuation of CSII during the hospital stay (93%) “important.” While most respondents (64%) acknowledged knowing the existence of their institution's policies for CSII use, only 84% of those respondents felt somewhat to very familiar with the policy. The most common barrier to CSII use in the inpatient setting was lack of practitioner (70%) and nursing (67%) knowledge of using the device. With regard to CGM use in the hospital, a minority (28%) of respondents were aware of their institution's CGM policies. Less than half of the providers, 43.8%, stated that, when admitting a patient, they reviewed CGM data to guide insulin dosing. Conclusions: In this US multicenter survey, we found that most inpatient practitioners valued glycemic control, but many were not familiar with institutional policies, had lack of knowledge with CSII, and were not reviewing CGM data.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/dia.2022.0226

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 17 · Cited by 9

Authors
Madhun, N. Z., Galindo, R. J., Donato, J., Hwang, P. R., Shabir, H. F., Fowler, M. J., Molitch-Hou, E., Bena, J. F., Umpierrez, G. E., & Lansang, M. C.
Affiliations
  • Cleveland Clinic (US)
  • Emory University (US)
  • Vanderbilt University Medical Center (US)
  • University of Chicago (US)
Corresponding author
Lansang, M. Cecilia
Venue
Diabetes Technology & Therapeutics
Published
2023-01-01
Volume
25
Issue
1
Pages
39-49
ISSN
  • 1520-9156 (ISSN-L)
  • 1557-8593
OpenAlex
W4307971811
Cited by
9
References
17
Citations by year
2026: 1 · 2025: 2 · 2024: 2 · 2023: 4
FWCI
1.48
Type
journal article
Language
en
Open access
Locations
  • Diabetes Technology & Therapeutics (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (UL1TR002378)
  • National Institute of Diabetes and Digestive and Kidney Diseases (K23DK123384, P30DK111024)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
diabetes technology, insulin pump therapy, continuous glucose monitoring, inpatient diabetes management, hyperglycemia treatment, provider attitudes, technology adoption barriers, glycemic control, insulin dose, hospitalists, advanced practice providers
MeSH terms
Blood Glucose, Diabetes Mellitus, Type 1, Hospitals, Humans, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Surveys and Questionnaires, Blood Glucose Self-Monitoring

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review